Innophos (IPHS) Scheduled to Post Quarterly Earnings on Monday

Innophos (NASDAQ:IPHS) will issue its quarterly earnings data after the market closes on Monday, February 19th. Analysts expect the company to announce earnings of $0.55 per share for the quarter.

Innophos (NASDAQ IPHS) opened at $41.72 on Monday. The stock has a market capitalization of $814.75, a P/E ratio of 19.23 and a beta of 0.76. The company has a current ratio of 2.86, a quick ratio of 1.49 and a debt-to-equity ratio of 0.83. Innophos has a 1 year low of $40.45 and a 1 year high of $58.22.

A number of equities analysts have commented on IPHS shares. KeyCorp reissued a “hold” rating on shares of Innophos in a report on Wednesday, November 1st. BidaskClub cut Innophos from a “hold” rating to a “sell” rating in a report on Tuesday, December 5th. Finally, Zacks Investment Research cut Innophos from a “buy” rating to a “hold” rating in a report on Thursday, December 14th.

TRADEMARK VIOLATION WARNING: “Innophos (IPHS) Scheduled to Post Quarterly Earnings on Monday” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/12/innophos-iphs-scheduled-to-post-quarterly-earnings-on-monday.html.

About Innophos

Innophos Holdings, Inc is a producer of nutritional specialty ingredients with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. The Company also provides bioactive mineral and nutritional ingredients. The Company’s segments include Specialty Phosphates US & Canada, Specialty Phosphates Mexico, and Granular Triple Super Phosphate (GTSP) & Other.

Earnings History for Innophos (NASDAQ:IPHS)

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply